Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Christopher Barker, MD
Memorial Sloan Kettering Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Cedars-Sinai Medical Center
Los Angeles, California, United States
- Memorial Sloan Kettering at Basking Ridge
Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States
- Memorial Sloan Kettering Cancer Center @ Suffolk
Commack, New York, United States
- Memorial Sloan Kettering Westchester
Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Memorial Sloan Kettering at Mercy Medical Center
Rockville Centre, New York, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 3 Jun 2016
- Primary completion
- 26 Sept 2017
- Completion
- 12 Oct 2022
- Last update posted
- 19 Oct 2022
- Registered enrollment
- 17
- Registry id
- NCT02730130
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.